S'abonner

Long-term complications after infection with SARS-CoV-1, influenza and MERS-CoV – Lessons to learn in long COVID? - 15/11/23

Doi : 10.1016/j.idnow.2023.104779 
F.B. Løkke a, K.S. Hansen a, d, L.S. Dalgaard b, K. Öbrink-Hansen b, B. Schiøttz-Christensen a, c, S. Leth b, d,
a Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark 
b Department of Infectious Diseases & Internal Medicine, Gødstrup Hospital, Gødstrup, Denmark 
c Research Unit of General Practice, Department of Public Health, University of Southern, Denmark 
d Department of Clinical Medicine, Aarhus University, Aarhus, Denmark 

Corresponding author at: Department of Infectious Diseases & Internal Medicine, Gødstrup Hospital, Hospitalsparken 15, 7400 Herning, Denmark.Department of Infectious Diseases & Internal MedicineGødstrup HospitalHospitalsparken 15Herning7400Denmark

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Highlights

Influenza, MERS-CoV, SARS-CoV-1 and SARS-CoV-2 potentially cause long-term sequelae.
There may be similarities in the mechanisms underlying long-term sequelae for these illnesses, such as persistent inflammation and immune dysregulation.
The long-term effects of COVID-19 are still being actively researched, and it is unclear how they compare to the long-term effects of influenza, MERS-CoV, and SARS-CoV-1.
There is a need to develop standardized measures on post-acute infection syndromes, effective interventions, as well as treatments to manage long-term sequelae and to prevent long-term disability and improve patient outcomes.

Le texte complet de cet article est disponible en PDF.

Abstract

The COVID-19 pandemic has affected millions of people worldwide, and while the mortality rate remains the primary concern, it is becoming increasingly apparent that many COVID-19 survivors experience long-term sequelae, representing a major concern for both themselves and healthcare providers. Comparing long-term sequelae following COVID-19 to those of other respiratory viruses such as influenza, MERS-CoV, and SARS-CoV-1 is an essential step toward understanding the extent and impact of these sequelae.

A literature search was carried out using the PubMed. database. Search-terms included “persistent”, “long-term”, “chronic”, and MeSH-terms for SARS-CoV-1, MERS-CoV and Influenza. Only English-language articles were selected. Articles were screened by title/abstract and full-text readings. Key points for comparison were persistent symptoms > 4 weeks, virus type, study design, population size, admission status, methods, and findings.

Thirty-one articles were included: 19 on SARS-CoV-1, 10 on influenza, and 2 on MERS-CoV-survivors. Damage to the respiratory system was the main long-term manifestation after the acute phase of infection. Quality of life-related and psychological sequelae were the second and third most widely reported symptoms, respectively. Consistent with long-term sequelae from COVID-19, persisting cardiovascular, neurological, musculoskeletal, gastrointestinal impairments were also reported.

In summary, the long-term sequelae following COVID-19 are a significant concern, and while long-term sequelae following influenza, MERS-CoV, and SARS-CoV-1 have also been reported, their prevalence and severity are less clear. It is essential to continue to study and monitor the long-term effects of all respiratory viruses so as to improve our understanding and develop strategies for prevention and treatment.

Le texte complet de cet article est disponible en PDF.

Keywords : Influenza, Long COVID-19, MERS-CoV, SARS-CoV-1, Sequelae


Plan


© 2023  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 53 - N° 8

Article 104779- octobre 2023 Retour au numéro
Article précédent Article précédent
  • Editorial board
| Article suivant Article suivant
  • Risk factors and prognostic significance of infection of totally implantable vascular access port in solid tumor patients: A prospective cohort study
  • Amaury Bailleul, Jean-Pierre Fulgencio, Sophie Vimont, Cécile Mordelet, Benoit Ray, Ludovic Lassel, Nathanaël Lapidus, Christophe Quesnel, Marc Garnier

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.